JAGUAR HEALTH, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
JAGUAR HEALTH, INC. (JAGX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of -0.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-04-07
- JAGUAR HEALTH, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was -0.50%.
- JAGUAR HEALTH, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was -62.60%, a 1377.55% decline from fiscal 2023.
- JAGUAR HEALTH, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was 4.90%, a 13.95% increase from fiscal 2022.
- JAGUAR HEALTH, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2022 was 4.30%, a 26.47% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.50% 10-K · filed 2026-04-07 | |
| 2024-12-31 | -62.60% 10-K · filed 2026-04-07 | 62.60% 10-K · filed 2025-03-31 |
| 2023-12-31 | 4.90% 10-K · filed 2025-03-31 | |
| 2022-12-31 | 4.30% 10-K · filed 2024-04-01 | |
| 2021-12-31 | 3.40% 10-K · filed 2023-03-24 | 1.80% 10-K · filed 2022-03-11 |
| 2020-12-31 | 3.40% 10-K · filed 2022-03-11 | |
| 2019-12-31 | 0.50% 10-K · filed 2021-03-31 | |
| 2018-12-31 | 1.00% 10-K · filed 2020-04-03 | |
| 2017-12-31 | 3.60% 10-K · filed 2019-04-10 | |
| 2016-12-31 | 1.80% 10-K · filed 2018-04-09 | |
| 2015-12-31 | 1.70% 10-K · filed 2017-02-15 | |
| 2014-12-31 | 2.20% 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |